HI
VERV

Harbour Investments’s Verve Therapeutics VERV Stock Holding History

Harbour Investments’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$19.4K – 3097
2022
Q4 		$19.4K Buy
+1,000
New +$26.5K ﹤0.01% 1689

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Harbour Investments's VERV Position: Q1 2023 in Review

Harbour Investments sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 1,000 shares — an estimated $19.4K sold.

Harbour Investments first reported a position in VERV in Q4 2022 and held it in 1 quarter. The position peaked at $19.4K in Q4 2022. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

  • Harbour Investments reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Harbour Investments sold 1,000 Verve Therapeutics shares in Q1 2023, an estimated $19.4K.
  • Harbour Investments first reported a position in Verve Therapeutics in Q4 2022 and held it in 1 quarter.
  • Harbour Investments's Verve Therapeutics position peaked at $19.4K in Q4 2022.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on Harbour Investments's 13F filing for Q1 2023, filed 15 May 2023.